KURA Latest Headlines

Kura Oncology rises following Jim Cramer comments

at seekingalpha.com (Mon, 22-Dec 12:01 PM)

Kura Oncology Sets Virtual Investor Event to Unveil ASH 2025 Data on Triplet AML Therapy

Market Chameleon (Thu, 4-Dec 11:54 AM)

FDA Approval of KOMZIFTI Sets New Standard for NPM1-Mutated AML Treatment—Kura Oncology Leads With Once-Daily Oral Therapy

Market Chameleon (Fri, 14-Nov 11:10 AM)

Kura Oncology's Cash Position Remains Strong Amid Ziftomenib Program Acceleration and Broader Pipeline Progress

Market Chameleon (Tue, 4-Nov 8:30 AM)

Kura Oncology Secures $30 Million Milestone as Ziftomenib Phase 3 AML Trial Advances

Market Chameleon (Mon, 27-Oct 11:54 AM)

Kura Oncology Receives $30 Million Milestone, Advancing Pivotal Ziftomenib Trials in AML

Market Chameleon (Fri, 24-Oct 7:32 AM)

Ziftomenib Shows Significant Clinical Benefit in Tough-to-Treat NPM1-Mutated AML: KOMET-001 Results Published in Journal of Clinical Oncology

Market Chameleon (Fri, 26-Sep 9:52 AM)